PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. The investigators are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of perampanel use for post-cardiac arrest status epilepticus (PCARSE) prevention after cardiac arrest.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥18 years old

• Non-traumatic, out-of-hospital cardiac arrest

• Comatose on admission - defined as not following commands

• Return of spontaneous circulation (ROSC) within less than 45 minutes from the time of cardiac arrest (defined as the time of 911 or EMS (emergency medical services) witnessed arrest)

• Admission to the intensive care unit at Zuckerberg San Francisco General Hospital

Locations
United States
California
Zuckerberg San Francisco General Hospital
RECRUITING
San Francisco
Contact Information
Primary
Edilberto Amorim, MD
prosperstudy@ucsf.edu
628-206-3203
Backup
Kevin Bao, BA
prosperstudy@ucsf.edu
Time Frame
Start Date: 2024-05-20
Estimated Completion Date: 2026-10-20
Participants
Target number of participants: 52
Treatments
Active_comparator: Perampanel
Perampanel oral load of 24mg upon randomization followed by 8mg oral dose daily for four more days (second dose one day after load and total treatment duration is 5 days)
Placebo_comparator: Placebo
Placebo oral load upon randomization followed by daily placebo oral dose administration for four more days (second dose one day after load and total placebo administration duration is 5 days)
Sponsors
Leads: University of California, San Francisco

This content was sourced from clinicaltrials.gov